Oxidative stress induced paclitaxel-derived carbon dots inhibit glioblastoma proliferation and EMT process

Haiyang Yan1,2, Huimin Miao1,2, Jiukun Hu1,2

  • 1School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.

PubMed

Insights

Novel carbon dots (CDs) synthesized from paclitaxel (PTX) effectively cross the blood-brain barrier to treat glioblastoma. These PTX-CDs target mitochondria, inhibit tumor growth, and improve survival in preclinical models.

Area of Science:

  • Nanomedicine
  • Oncology
  • Biochemistry

Background:

  • Glioblastoma is an aggressive brain tumor with limited treatment options.
  • The blood-brain barrier (BBB) restricts drug delivery to the brain.
  • Carbon dots (CDs) show potential for brain disease theranostics.

Purpose of the Study:

  • To synthesize and characterize novel paclitaxel-derived carbon dots (PTX-CDs).
  • To evaluate the BBB penetration and anticancer efficacy of PTX-CDs.
  • To investigate the underlying mechanisms of PTX-CDs in glioblastoma treatment.

Main Methods:

  • One-step hydrothermal synthesis of PTX-CDs using paclitaxel (PTX) precursor.
  • Assessment of water solubility, BBB penetration, and cellular uptake.
  • Mitochondrial accumulation, ROS generation, cell cycle arrest (G2/M), and EMT inhibition analysis.
  • In vivo efficacy studies in an orthotopic glioblastoma mouse model.

Main Results:

  • PTX-CDs exhibited ~1000-fold increased water solubility compared to PTX.
  • PTX-CDs effectively crossed the BBB and accumulated in glioblastoma mitochondria.
  • PTX-CDs induced mitochondrial damage, increased ROS, caused G2/M cell cycle arrest, and inhibited EMT.
  • PTX-CDs significantly suppressed tumor growth and prolonged survival in mice.

Conclusions:

  • PTX-CDs represent a promising nano-formulation for glioblastoma treatment.
  • This strategy facilitates drug delivery across the BBB for brain tumors.
  • PTX-CDs offer a viable approach for developing novel glioblastoma therapeutics.